uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
30.44
-3.85 (-11.23%)
At close: Nov 4, 2025, 4:00 PM EST
28.97
-1.47 (-4.83%)
After-hours: Nov 4, 2025, 7:59 PM EST
uniQure Revenue
uniQure had revenue of $5.26M in the quarter ending June 30, 2025, a decrease of -52.71%. This brings the company's revenue in the last twelve months to $14.34M, down -48.25% year-over-year. In the year 2024, uniQure had annual revenue of $27.12M with 71.17% growth.
Revenue (ttm)
$14.34M
Revenue Growth
-48.25%
P/S Ratio
109.70
Revenue / Employee
$68,598
Employees
209
Market Cap
1.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
QURE News
- 1 day ago - UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data - Benzinga
- 1 day ago - QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - Business Wire
- 1 day ago - uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE - Business Wire
- 1 day ago - Biotech is back. Here's why these rallying stocks belong in your portfolio now. - Market Watch
- 1 day ago - UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why. - Barrons
- 1 day ago - FDA says clinical data for UniQure's Huntington's disease therapy not adequate - Reuters
- 1 day ago - uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease - GlobeNewsWire
- 7 days ago - uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade) - Seeking Alpha